Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
June 01, 2017 09:05 ET
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...